Bionomics Limited/fi DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Leading proxy advisory firm ISS recommends Neuphoria shareholders vote for the company's director nominees, supporting the board's strategic review amidst a proxy contest.
Neuphoria Therapeutics Inc. has rejected a revised, lower acquisition bid from Lynx1 Master Fund LP, emphasizing its ongoing strategic review and urging shareholders to support its current board nominees.
Neuphoria Therapeutics Inc. issued statements to counter what it believes are deceptive claims by activist investor Lynx1 Master Fund LP, urging stockholders to support its current board nominees.
Neuphoria Therapeutics Inc. is defending its current board nominees and strategic review process against a dissident proxy contest initiated by Lynx1 Master Fund LP.
Neuphoria Therapeutics Inc. urges stockholders to vote for its director nominees to ensure stability during a critical strategic review process, following a failed Phase 3 clinical trial.
Neuphoria Therapeutics Inc. issues its definitive proxy statement for its December 12, 2025 Annual Meeting, facing a proxy contest from activist investor LYNX1 Master Fund LP and addressing key governance proposals following a significant clinical trial failure.
Lynx1 Master Fund LP, Neuphoria's largest shareholder, is soliciting proxies to elect two independent directors to the Board following the company's failed Phase 3 trial and subsequent dilutive share issuance.
Neuphoria Therapeutics Inc. announced a strategic review to maximize stockholder value, confirming an unsolicited non-binding acquisition offer of $5.20 per share from Lynx1 Master Fund LP and director nominations.
Neuphoria Therapeutics Inc. has filed definitive additional materials related to a proxy statement with the SEC.
Neuphoria Therapeutics Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 9, 2025, to vote on director elections, auditor ratification, and executive compensation matters.
DEFA14A: Bionomics Corrects Record Date Details for Neuphoria Share Distribution in Re-domiciliation Scheme
Bionomics has filed a supplement to its proxy statement to correct an error regarding the record date for ADS holders to receive Neuphoria shares in the proposed re-domiciliation scheme.
Bionomics Limited is seeking shareholder approval to re-domicile from Australia to Delaware through a scheme of arrangement, with Neuphoria Therapeutics Inc. acquiring all outstanding shares.